Therapeutic options for treatment-experienced patients: A focus on resistance testing and optimizing background therapy

AIDS Reader

Volumn 16, Issue 5, 2006, Pages

  Sax, Paul E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HIV AIDS; Resistance testing; Second line therapy; Treatment failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; PATIENT CARE; REVIEW; TREATMENT FAILURE;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PATIENT CARE MANAGEMENT; TREATMENT FAILURE;

EID: 33745169365     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated Octo-ber 6, 2005. Available at:http://aidsirvfo.nih.gov/guidelines. Accessed March 31,2006.
2. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Anti- retroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2003;37:113-128.
3. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5:352-359.
4. Sebastian J, Faruki H. Update on HIV resistance and resistance testing. Med Res Rev. 2004;24:115-125.
5. Lalezari JP, Henry K, O'Hearn M, et al; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [published correction appears in N Engl ] Med. 2003;349:1100]. N Engl J Med. 2003;348:2175- 2185.
6. Hicks C. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington DC. Abstract H-1137a.
7. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large anti-retroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection [published correction appears in Ann Intern Med. 2002;136:253]. Ann Intern Med. 2000;133:21-30.
9. Bangsberg DR, Weiser SD, Guzman D, Riley ED. 95% Adherence is not necessary to suppress the majority of individuals to less than 400 copies/mL on NNRTI regimens. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 616.
10. Musey LK, Krieger IN, Hughes JP, et al. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 1999;180:278-284.
11. Gulick RM. Assessing the benefits of antiretroviral therapy. Ann Intern Med.2000;133:471-473.
12. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953.
13. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004;18:1539-1548.
14. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-l-infected individuals with vi-rological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
15. Miller V, Phillips AN, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis. 2002;186:189-197.
16. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with mul-tidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846.
17. Paredes R, Puig T, Arno A, et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr. 1999;22:132-138.
18. Montaner J, Guimaraes D, Chung J, et al. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials. 2005;6:281- 290.
19. Grinsztejn B, Hicks C, Cahn P, et al. Tipranavir/ritonavir (TPV/r) demonstrates superior immunologic response to comparator protease inhibitors (CPIs) in a Pi-experienced population with advanced disease. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27,2005; Rio de Janeiro. Abstract WePel6.7B07.
20. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
21. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-989.
22. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis. 2006;193:259-268.
23. Negredo E, Bonjoch A, Paredes R, et al. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis. 2005;41:901-905.
24. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42: 418-427.
25. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
26. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
27. MacManus S, Yates PJ, Elston RC, et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651-655.
28. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
29. Bennett D, McCormick L, Kline R, et al. US Surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 674.
30. Lazzarin A, Clotet B, Cooper D, et al; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
31. Cahn P and the RESIST-2 Study Team. 24-Week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients. Presented at the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, UK. Abstract PL 14.3.
32. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS. 2004;18:217-226.
33. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-1401.
34. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19:487-494.
35. Masquelier B, Costagliola D, Schmuck A, et al. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-in- fected patients: a French nationwide study. J Med Virol. 2005;76:441-446.
36. Hogg RS, Bangsberg D, Alexander C, et al. Drug resistance is associated with an increased risk of death in patients first starting HAART. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 712.
37. Grover D, Allen L, Pillay D, et al. Predictors of death, and response to therapy in patients with multi(three)-class drug resistant HTV in the UK. An-tivir Ther. 2005;10(suppl 1):S7. Abstract 5.
38. Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDS. 2004; 18:199-208.
39. Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188:992-1000.
40. Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2003;34(suppl 1): S2-S7.
41. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995;69:5228-5235.
42. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. An-timicrob Agents Chemother. 1998;42:2775-2783.
43. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. An- timicrob Agents Chemother. 1998;42:2637-2644.
44. Mellors J, Palmer S, Nissley D, et al. Low-frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimens. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11,2004; San Francisco. Abstract 39.
45. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-413.
46. Masquelier B, Tamalet C Montes B, et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther. 2004;9:315-323.
47. Landman R, Descamps D, Trylesinski A, et al. Successful rescue therapy in patients developing K65R on tenofovir containing regimens: long-term follow-up. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 710.
48. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in anti-retroviral-experienced patients. J Infect Dis. 2004;189: 837-846.
49. Ciancio BC, Trotta MP, Lorenzini P, et al. The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy. Antivir Ther. 2003;8: 611-616.
50. Haubrich R, Best B, Witt M, et al. Determinants of the need for therapeutic drug monitoring: rates and predictors from CCTG 578. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 640.
51. Haubrich RH. Resistance and replication capacity assays: clinical utility and interpretation. Top HIV Med. 2004;12:52-56.
52. Perez-Elias MJ, Garcia-Arota I, Munoz V, et al; Realvirfen study group. Phenotype or virtual phe- notype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther. 2003;8:577-584.
53. Saracino A, Monno L, Locaputo S, et al. Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). J Acquir Immune Defic Syndr. 2004;37:1587-1598.
54. Albrecht D, Zöllner B, Feucht HH, et al. Reap-pearance of HIV multidrug-resistance in plasma and circulating lymphocytes after rein traduction of anti-retroviral therapy. J Clin Virol. 2002;24:93-98.
55. Delaugerre C, Valantin MA, Mouroux M, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS. 2001,T5:2189- 2191.
56. Lambotte O, Chaix ML, Gubler B, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS. 2004; 18:1147-1158.
57. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother. 2004;54:6-9.
58. Blanco J, Guelar A, Domingo P, et al. Genotypic vs real phenotypic tests to guide salvage antiretrovi-ral therapy in heavily preheated patients with viro-logical failure: a 48 weeks prospective, randomized study (VIHRES Study). Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 675.
59. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2003; 348:2228-2238.
60. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137-1146.
61. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Aafuir Immune Defic Syndr. 2003;34(suppl 1):S91-S94.
62. Arasteh K, Clumeck N, Pozniak A, et al. Anti- retroviral activity, safety and pharmacokinetics of TMC114, a next-generation HIV-1 protease inhibitor (PI), in multiple Pl-experieneed patients. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16,2003; Paris. Abstract LB16.
63. Koh Y, Nakata H, Maeda K, et al. Novel bis- tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3123-3129.
64. Katlama C, Arastéh K, Clotet B, et al. Enfuvirtide TORO studies: 48-week results confirm 24-week findings. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16,2003; Paris. Abstract LB02.
65. Schapiro J, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: the phase 3 RESIST-1 and -2 trials. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25 2005; Boston. Abstract 104.
66. Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract LB164.
67. Katlama C, Carvalho MT, Cooper D, et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213). Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27 2005; Rio de Janeiro. Abstract WeOaLB0102.
68. Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the POWER 2 study (C202). Presented at the 45th Inter-science Conference on Antimicrobial Agents and Chemotherapy; December 16-19,2005; Washington, DC. Abstract H-413.
69. Cohen C, Katlama C, Murphy R, et al. Antiretro-viral activity and tolerability of Reverset (D-d4FC), a new fluorocytidine nucleoside analog, when used in combination therapy in treatment-experienced patients: results of phase lib study RVT-203. Presented at the 3rd International AIDS Society Conference; July 24-27,2005; Rio de Janeiro. Abstract WeOaLB103.
70. Ward D, Lalezari J, Thompson M, et al. Preliminary antiviral activity and safety of 640385/ritonavir in HIV-infected patients (Study HPR10006): an 8-week interim analysis. Presented at the 45th Inter-science Conference on Antimicrobial Agents and Chemotherapy; December 16-19,2005; Washington, DC. Abstract H-412.
71. Grossman HA, Hicks C, Nadler J, et al. Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19,2005; Washington, DC. Abstract H-416c.
72. Grinsztejn B, Nguyen BY, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 inte- grase inhibitor, in patients with triple-class resistant virus. Presented at the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 160LB.
73. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
74. Schurmann D, Rouzier R, Nougarede R, et al. SCH D: antiviral activity of a CCR5 receptor antagonist. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11,2004; San Francisco. Abstract 140LB.
75. Beatty G, Lalezari L, Eron J, et al. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract H-416d.